ouabain has been researched along with Esophageal Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Folts, CJ; Gao, X; Jiang, M; Lan, X; Lin, S; Liu, K; Lu, R; Noble, MD; Que, J; Zhang, Y; Zhao, T; Zhou, Z | 1 |
Hayashi, H; Hazama, S; Hirose, K; lizuka, N; Miyamoto, K; Oka, M; Tangoku, A; Yoshida, H; Yoshimura, K; Yoshino, S | 1 |
2 other study(ies) available for ouabain and Esophageal Neoplasms
Article | Year |
---|---|
Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Digitoxin; Digoxin; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; MAP Kinase Kinase 6; Mice, Inbred NOD; Ouabain; Protein Kinase Inhibitors; Signal Transduction; SOX9 Transcription Factor; Xenograft Model Antitumor Assays | 2018 |
Downregulation of intracellular nm23-H1 prevents cisplatin-induced DNA damage in oesophageal cancer cells: possible association with Na(+), K(+)-ATPase.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Cisplatin; DNA; DNA Damage; DNA Fragmentation; DNA, Antisense; DNA, Mitochondrial; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Esophageal Neoplasms; Humans; Monomeric GTP-Binding Proteins; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Ouabain; Sodium-Potassium-Exchanging ATPase; Transcription Factors; Transfection; Tumor Cells, Cultured | 2000 |